EUVIMEDOpdag EUVIMED
Open access

Cyclin Y interacts with Chk1 to activate RRM2/STAT3 signaling and promotes radioresistance in non-small cell lung cancer

Zhiwei Liu, Huichan Xue, Zhi Wang, Ye Zhao, Shuangbing Xu, Xiaorong Dong

International Journal of Biological Sciences · 2025

DOI: 10.7150/ijbs.106925 ↗

At a glance

Journal article in International Journal of Biological Sciences, 2025. Written by Zhiwei Liu and 5 co-authors. Institution: Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China. Major MEDLINE topics: Carcinoma, Non-Small-Cell Lung, STAT3 Transcription Factor, Ribonucleoside Diphosphate Reductase, Lung Neoplasms. Cited 5 times so far (Crossref). The full text is freely available in PubMed Central.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Radioresistance is one of the main reasons for the recurrence and metastasis of non-small cell lung cancer. Cyclin Y has been implicated in various cellular processes such as cell growth, proliferation, autophagy, and tumor progression. However, the function and regulatory mechanism of Cyclin Y in lung cancer radioresistance remain poorly understood. In this study, we find that Cyclin Y is overexpressed in non-small cell lung cancer and correlates with poor prognosis. Furthermore, knockdown of Cyclin Y results in inhibited cell growth and proliferation, increases DNA damage, impairs DNA damage repair, and enhances radiosensitivity in vitro and in vivo. Mechanistically, we uncover that Cyclin Y interacts with Chk1 and positively regulate both the mRNA and protein levels of RRM2, resulting in increased STAT3 phosphorylation. Rescue experiments confirm that the effects of Cyclin Y on lung cancer are mediated partially by RRM2. Collectively, we reveal for the first time that Cyclin Y promotes lung cancer radioresistance by binding to Chk1 to activate RRM2/STAT3 signaling, indicating that targeting Cyclin Y may be a promising strategy for enhancing the efficacy of radiotherapy in the treatment of non-small cell lung cancer.

Subjects

MeSH terms (MEDLINE)

Carcinoma, Non-Small-Cell LungSTAT3 Transcription FactorRibonucleoside Diphosphate ReductaseLung NeoplasmsCheckpoint Kinase 1CyclinsHumansSignal TransductionRadiation ToleranceAnimalsCell Line, TumorMiceCell ProliferationMice, NudeDNA DamageFemaleMice, Inbred BALB CMalePhosphorylation

Author keywords

Chk1RRM2cyclin Ynon-small cell lung cancerradioresistance

Substances

STAT3 Transcription FactorRibonucleoside Diphosphate ReductaseCheckpoint Kinase 1ribonucleotide reductase M2CyclinsCHEK1 protein, humanSTAT3 protein, human

Authors and institutions

  • Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
  • Hubei Key Laboratory of Precision Radiation Oncology, Wuhan 430022, China.
  • Institute of Radiation Oncology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.

Cite

APA

Liu, Z., Xue, H., Wang, Z., Zhao, Y., Xu, S., & Dong, X. (2025). Cyclin Y interacts with Chk1 to activate RRM2/STAT3 signaling and promotes radioresistance in non-small cell lung cancer. International Journal of Biological Sciences. https://doi.org/10.7150/ijbs.106925

Vancouver

Liu Z, Xue H, Wang Z, Zhao Y, Xu S, Dong X. Cyclin Y interacts with Chk1 to activate RRM2/STAT3 signaling and promotes radioresistance in non-small cell lung cancer. International Journal of Biological Sciences. 2025. doi:10.7150/ijbs.106925

BibTeX
@article{Liu2025,
  author = {Liu, Zhiwei and Xue, Huichan and Wang, Zhi and Zhao, Ye and Xu, Shuangbing and Dong, Xiaorong},
  title = {Cyclin Y interacts with Chk1 to activate RRM2/STAT3 signaling and promotes radioresistance in non-small cell lung cancer},
  journal = {International Journal of Biological Sciences},
  year = {2025},
  doi = {10.7150/ijbs.106925}
}
Start for free →